(S)-10-Hydroxycamptothecin (Synonyms: 10-HCPT; 10-Hydroxycamptothecin)

Cat. No.: HY-N0095 Purity: 99.38%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

(S)-10-Hydroxycamptothecin (10-HCPT;10-Hydroxycamptothecin) is a DNA topoisomerase I inhibitor of isolated from the Chinese plant Camptotheca accuminata. (S)-10-Hydroxycamptothecin exhibits a remarkable apoptosis-inducing effect. (S)-10-Hydroxycamptothecin has the potential for hepatoma, gastric carcinoma, colon cancer and leukaemia treatment.

For research use only. We do not sell to patients.

(S)-10-Hydroxycamptothecin Chemical Structure

CAS No. : 19685-09-7

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 87	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 87	In-stock	Estimated Time of Arrival: December 31
Solid
50 mg	USD 79	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 119	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of (S)-10-Hydroxycamptothecin:

(S)-10-Hydroxycamptothecin-d5 Get quote
(±)-10-Hydroxycamptothecin Get quote
(S)-10-Hydroxycamptothecin (Standard) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All Isoforms

Topoisomerase Topo I Topo II

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]^[3]

Topoisomerase I

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.004 μM Compound: 2	Cytotoxicity against human A2780 cells overexpressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay Cytotoxicity against human A2780 cells overexpressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay	[PMID: 22959246]
A2780	IC₅₀	0.7 μM Compound: 2, HCPT	Cytotoxicity against human A2780 cells after 48 hrs by MTT assay Cytotoxicity against human A2780 cells after 48 hrs by MTT assay	[PMID: 19715319]
A-375	IC₅₀	0.15 μM Compound: HCPT	Cytotoxicity against human A375 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A375 cells after 72 hrs by sulforhodamine B assay	[PMID: 23639650]
A-375	IC₅₀	27.8 μM Compound: HCPT	Cytotoxicity against human A375 cells after 72 hrs by MTT assay Cytotoxicity against human A375 cells after 72 hrs by MTT assay	[PMID: 26280921]
A-375	IC₅₀	27.8 μM Compound: HCPT	Cytotoxicity against human A375 cells after 72 hrs by MTT assay Cytotoxicity against human A375 cells after 72 hrs by MTT assay	[PMID: 25874331]
A549	IC₅₀	0.07 μM Compound: 10-OH CPT	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 23566520]
A549	IC₅₀	0.08 μM Compound: 10-HCPT	Cytotoxicity against human A549 assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human A549 assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
A549	IC₅₀	0.082 μM Compound: HCPT	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 26725027]
A549	IC₅₀	0.11 μM Compound: 6, CPT-OH	Antitumor activity against human A549/ATCC cells by SRB method Antitumor activity against human A549/ATCC cells by SRB method	[PMID: 19541483]
A549	IC₅₀	0.3 μM Compound: HCPT	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 23639650]
A549	IC₅₀	0.8 μM Compound: HCPT	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28441581]
A549	IC₅₀	0.8 μM Compound: HCPT	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 27836197]
A549	IC₅₀	1.75 μM Compound: HCPT	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29921475]
A549	IC₅₀	2.75 μM Compound: HCPT	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 30108853]
A549	IC₅₀	33.6 nM Compound: 10-HCPT	Cytotoxicity against human A549 after 72 hrs by SRB assay Cytotoxicity against human A549 after 72 hrs by SRB assay	[PMID: 22647222]
A549	IC₅₀	9.13 μM Compound: HCPT	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30528976]
Bcap37	IC₅₀	> 20 μM Compound: HCPT	Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay	[PMID: 23124210]
Bcap37	IC₅₀	28.1 μM Compound: HCPT	Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay	[PMID: 26280921]
Bcap37	IC₅₀	28.1 μM Compound: HCPT	Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay	[PMID: 25874331]
Bel-7402	IC₅₀	0.2 μM Compound: 2, HCPT	Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay	[PMID: 19715319]
Bel-7402	IC₅₀	0.2 μM Compound: 10-OH CPT	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 23566520]
Bel-7402	IC₅₀	0.28 μM Compound: HCP	Cytotoxicity against human Bel-7402 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human Bel-7402 cells after 72 hrs by sulforhodamine B assay	[PMID: 17067169]
Bel-7402	IC₅₀	0.36 μM Compound: HCP	Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay	[PMID: 20184290]
Bel-7402	IC₅₀	0.4 μM Compound: HCP	Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay	[PMID: 19133759]
CNE-2	IC₅₀	0.37 μM Compound: HCPT	Cytotoxicity against human CNE2 cells after 48 hrs by MTT assay Cytotoxicity against human CNE2 cells after 48 hrs by MTT assay	[PMID: 19423199]
CNE-2	IC₅₀	1.04 μM Compound: 10-HCT	Antitumor against human CNE2 cells assessed as cell survival after 48 hrs by MTT assay Antitumor against human CNE2 cells assessed as cell survival after 48 hrs by MTT assay	[PMID: 21600681]
COLO 205	IC₅₀	9.1 nM Compound: 2	Cytotoxicity against human Colo 205 cells assessed as inhibition of [3H]thymidine after 48 hrs Cytotoxicity against human Colo 205 cells assessed as inhibition of [3H]thymidine after 48 hrs	[PMID: 18318465]
HCT-116	IC₅₀	0.021 μM Compound: 10-HCPT	Cytotoxicity against human HCT-116 assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
HCT-116	IC₅₀	0.05 μM Compound: 10-HCPT	Antiproliferative activity against human HCT-116 cells incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells incubated for 24 hrs by CCK-8 assay	[PMID: 35561631]
HCT-116	IC₅₀	0.3 μM Compound: 10-OH CPT	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 23566520]
HCT-116	IC₅₀	3.2 μM Compound: HCPT	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 28441581]
HCT-116	IC₅₀	3.5 μM Compound: HCPT	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 27836197]
HCT-116	IC₅₀	31.2 nM Compound: 10-HCPT	Cytotoxicity against human HCT116 after 72 hrs by SRB assay Cytotoxicity against human HCT116 after 72 hrs by SRB assay	[PMID: 22647222]
HCT-116	IC₅₀	58.62 μM Compound: HCPT	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 26725027]
HCT-8	IC₅₀	0.181 μM Compound: 2	Antiproliferative activity against human HCT8 cells after 48 hrs by CCK8 assay Antiproliferative activity against human HCT8 cells after 48 hrs by CCK8 assay	[PMID: 25481395]
HeLa	IC₅₀	0.06 μM Compound: 10-HCPT	Antiproliferative activity against human HeLa cells incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells incubated for 24 hrs by CCK-8 assay	[PMID: 35561631]
HeLa	IC₅₀	10.04 μM Compound: HCPT	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28318943]
HeLa	IC₅₀	29.16 μM Compound: HCPT	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 28745887]
HepG2	IC₅₀	0.499 μM Compound: 2	Antiproliferative activity against human HepG2 cells after 48 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells after 48 hrs by CCK8 assay	[PMID: 25481395]
HepG2	IC₅₀	0.981 μM Compound: 10-Hydroxy CPT	Antitumor activity against human HepG2 cells by WST-1 assay Antitumor activity against human HepG2 cells by WST-1 assay	[PMID: 21414778]
HepG2	IC₅₀	1.47 μM Compound: HCPT	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 30600208]
HepG2	IC₅₀	10.1 μM Compound: HCPT	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 27836197]
HepG2	IC₅₀	10.21 μM Compound: HCPT	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30528976]
HepG2	IC₅₀	10.3 μM Compound: HCPT	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28441581]
HepG2	IC₅₀	2.27 μM Compound: HCPT	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26725027]
HepG2	IC₅₀	3.19 μM Compound: HCPT	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29921475]
HepG2	IC₅₀	3.7 μM Compound: 10-Hydroxycamptothecin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 20402524]
HepG2	IC₅₀	5.4 nM Compound: 2	Cytotoxicity against human HepG2 cells assessed as inhibition of [3H]thymidine after 48 hrs Cytotoxicity against human HepG2 cells assessed as inhibition of [3H]thymidine after 48 hrs	[PMID: 18318465]
HepG2	IC₅₀	5.52 μM Compound: HCPT	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 28745887]
HepG2	IC₅₀	6.49 μM Compound: 10-hydroxy-camptothecin	Cytotoxicity against human Hep G2 after 48 hrs by MTT assay Cytotoxicity against human Hep G2 after 48 hrs by MTT assay	[PMID: 16933867]
HL-60	IC₅₀	0.04 μM Compound: 10-Hydroxycamptothecin	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 20402524]
HL-60	IC₅₀	0.11 μM Compound: 5ak	Inhibition of Topoisomerase I by cleavage complex formation in human HL-60 cells Inhibition of Topoisomerase I by cleavage complex formation in human HL-60 cells	[PMID: 8410981]
HL-60	IC₅₀	0.25 μM Compound: HCPT	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 23639650]
HL-60	IC₅₀	0.41 μM Compound: HCP	Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay	[PMID: 17067169]
HT-29	IC₅₀	0.21 μM Compound: 6, CPT-OH	Antitumor activity against human HT-29 cells by SRB method Antitumor activity against human HT-29 cells by SRB method	[PMID: 19541483]
HT-29	IC₅₀	8.8 nM Compound: 2	Cytotoxicity against human HT29 cells assessed as inhibition of [3H]thymidine after 48 hrs Cytotoxicity against human HT29 cells assessed as inhibition of [3H]thymidine after 48 hrs	[PMID: 18318465]
HUVEC	IC₅₀	18.2 μM Compound: HCPT	Antiproliferative activity against human HUVEC cells after 48 hrs by MTT assay Antiproliferative activity against human HUVEC cells after 48 hrs by MTT assay	[PMID: 28441581]
Jurkat	IC₅₀	0.03 μM Compound: 10-Hydroxycamptothecin	Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 20402524]
K562	IC₅₀	0.16 μM Compound: HCP	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 20184290]
K562	IC₅₀	4.1 μM Compound: HCP	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 19133759]
KB	IC₅₀	0.128 μM Compound: 2	Antiproliferative activity against human KB cells after 48 hrs by CCK8 assay Antiproliferative activity against human KB cells after 48 hrs by CCK8 assay	[PMID: 25481395]
KB	IC₅₀	0.6 μM Compound: 2, HCPT	Cytotoxicity against human KB cells after 48 hrs by MTT assay Cytotoxicity against human KB cells after 48 hrs by MTT assay	[PMID: 19715319]
KB	IC₅₀	0.6 μM Compound: 10-OH CPT	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 23566520]
KB	IC₅₀	0.829 μM Compound: 10-Hydroxy CPT	Antitumor activity against human KB cells by WST-1 assay Antitumor activity against human KB cells by WST-1 assay	[PMID: 21414778]
L02	IC₅₀	10.23 μM Compound: HCPT	Antiproliferative activity against human HL-7702 cells after 48 hrs by MTT assay Antiproliferative activity against human HL-7702 cells after 48 hrs by MTT assay	[PMID: 30528976]
L02	IC₅₀	12.83 μM Compound: HCPT	Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay	[PMID: 30108853]
L02	IC₅₀	20.4 μM Compound: HCPT	Antiproliferative activity against human L02 cells after 48 hrs by MTT assay Antiproliferative activity against human L02 cells after 48 hrs by MTT assay	[PMID: 28441581]
LoVo	IC₅₀	0.33 μM Compound: 10-HCPT	Cytotoxicity against human LoVo assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human LoVo assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
MCF7	IC₅₀	19.12 μM Compound: 10-hydroxy-camptothecin	Cytotoxicity against human MCF7 after 48 hrs by MTT assay Cytotoxicity against human MCF7 after 48 hrs by MTT assay	[PMID: 16933867]
MCF7	IC₅₀	2.4 μM Compound: HCPT	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 27836197]
MCF7	IC₅₀	2.8 μM Compound: HCPT	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28441581]
MCF7	IC₅₀	3.58 μM Compound: HCPT	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30600208]
MCF7	IC₅₀	48.2 μM Compound: HCPT	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 26280921]
MCF7	IC₅₀	48.2 μM Compound: HCPT	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 25874331]
MDA-MB-231	IC₅₀	0.06 μM Compound: 10-OH CPT	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 23566520]
MG-63	IC₅₀	10.69 μM Compound: HCPT	Antiproliferative activity against human MG63 cells after 48 hrs by MTT assay Antiproliferative activity against human MG63 cells after 48 hrs by MTT assay	[PMID: 30528976]
MGC-803	IC₅₀	> 20 μM Compound: HCPT	Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 23124210]
MGC-803	IC₅₀	15.19 μM Compound: HCPT	Antiproliferative activity against human MGC803 cells by MTT assay Antiproliferative activity against human MGC803 cells by MTT assay	[PMID: 28745887]
MGC-803	IC₅₀	29.1 μM Compound: HCPT	Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 26280921]
MGC-803	IC₅₀	29.1 μM Compound: HCPT	Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 25874331]
MGC-803	IC₅₀	6.55 μM Compound: HCPT	Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 30108853]
MGC-803	IC₅₀	6.55 μM Compound: HCPT	Cytotoxicity against human MGC803 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MGC803 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29921475]
MGC-803	IC₅₀	9.71 μM Compound: HCPT	Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 30528976]
NCI-H460	IC₅₀	10.08 μM Compound: HCPT	Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 30528976]
NCI-H460	IC₅₀	16.59 μM Compound: HCPT	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 30108853]
NCI-H460	IC₅₀	38.55 μM Compound: 10-hydroxy-camptothecin	Cytotoxicity against human NCI-H460 after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 after 48 hrs by MTT assay	[PMID: 16933867]
NCI-H460	IC₅₀	4.91 μM Compound: HCPT	Antiproliferative activity against human NCI-H460 cells by MTT assay Antiproliferative activity against human NCI-H460 cells by MTT assay	[PMID: 28745887]
PC-3	IC₅₀	0.078 μM Compound: 2	Cytotoxicity against human PC3 cells expressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay Cytotoxicity against human PC3 cells expressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay	[PMID: 22959246]
PC-3	IC₅₀	34.5 μM Compound: HCPT	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 26280921]
PC-3	IC₅₀	34.5 μM Compound: HCPT	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 25874331]
SF-268	IC₅₀	29.88 μM Compound: 10-hydroxy-camptothecin	Cytotoxicity against human SF-268 after 48 hrs by MTT assay Cytotoxicity against human SF-268 after 48 hrs by MTT assay	[PMID: 16933867]
SGC-7901	IC₅₀	0.835 μM Compound: 2	Antiproliferative activity against human SGC7901 cells after 48 hrs by CCK8 assay Antiproliferative activity against human SGC7901 cells after 48 hrs by CCK8 assay	[PMID: 25481395]
SMMC-7721	IC₅₀	0.14 μM Compound: HCP	Growth inhibition of human SMMC7721 cells after 48 hrs by MTT assay Growth inhibition of human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 19842682]
T-24	IC₅₀	11.83 μM Compound: HCPT	Cytotoxicity against human T24 cells after 48 hrs by MTT assay Cytotoxicity against human T24 cells after 48 hrs by MTT assay	[PMID: 30108853]
T-24	IC₅₀	11.83 μM Compound: HCPT	Cytotoxicity against human T24 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human T24 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29921475]
T-24	IC₅₀	5.53 μM Compound: HCPT	Antiproliferative activity against human T24 cells by MTT assay Antiproliferative activity against human T24 cells by MTT assay	[PMID: 28745887]
U-937	IC₅₀	0.11 μM Compound: 10-Hydroxycamptothecin	Cytotoxicity against human U937 cells after 48 hrs by MTT assay Cytotoxicity against human U937 cells after 48 hrs by MTT assay	[PMID: 20402524]

In Vitro

(S)-10-Hydroxycamptothecin (5-20 μg/L; 6 days; Hep G2 cells) treatment results in the cell cycle arrest at G2/M phase^[2].
(S)-10-Hydroxycamptothecin induces differentiation, down-regulates nuclear antigen (PCNA) and up-regulates wild-type protein p53 in Hep G2 cells^[2].
(S)-10-Hydroxycamptothecin inhibits L1210 leukemia cells with an IC₅₀ of 1.15 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[2]

Cell Line:	Hep G2 cells
Concentration:	5 µg/L, 10 µg/L, 20 µg/L
Incubation Time:	6 days
Result:	Hep G2 cells were mainly arrested at G2/M phase.

In Vivo

(S)-10-Hydroxycamptothecin (10-Hydroxycamptothecin) against L1210 leukemia in mice is tested. At the optimal dose (15 mg/kg), (S)-10-Hydroxycamptothecin has a 71% increase in life span (ILS)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

364.35

Formula

C₂₀H₁₆N₂O₅

CAS No.

19685-09-7

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=CC(O)=CC=C5N=C4C3=C2)=O

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (137.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7446 mL	13.7231 mL	27.4461 mL
5 mM	0.5489 mL	2.7446 mL	5.4892 mL
10 mM	0.2745 mL	1.3723 mL	2.7446 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (6.86 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (6.86 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.38%

Select Batch:

Data Sheet (277 KB) SDS (393 KB)

COA (253 KB) HNMR (171 KB) LCMS (584 KB)

Handling Instructions (2659 KB)

References

[1]. Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance . Journal of Drug Targeting.

[2]. Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance. J Drug Target, Early Online: 1–8

[3]. Yu P, et al. Synthesis and preliminary anticancer evaluation of 10-hydroxycamptothecin analogs. Biol Pharm Bull. 2012;35(8):1295-9. [Content Brief]

[4]. Zhang XW, et al. Differentiation-inducing action of 10-hydroxycamptothecin on human hepatoma Hep G2 cells. Acta Pharmacol Sin. 2000 Apr;21(4):364-8. [Content Brief]

[5]. Zhang XW, et al. Differential regulation of P53, c-Myc, Bcl-2, Bax and AFP protein expression, and caspase activity during 10-hydroxycamptothecin-induced apoptosis in Hep G2 cells. Anticancer Drugs. 2000 Oct;11(9):747-56. [Content Brief]

[6]. Liu M, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance. J Drug Target. 2016;24(5):433-40. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.7446 mL	13.7231 mL	27.4461 mL	68.6153 mL
	5 mM	0.5489 mL	2.7446 mL	5.4892 mL	13.7231 mL
	10 mM	0.2745 mL	1.3723 mL	2.7446 mL	6.8615 mL
	15 mM	0.1830 mL	0.9149 mL	1.8297 mL	4.5744 mL
	20 mM	0.1372 mL	0.6862 mL	1.3723 mL	3.4308 mL
	25 mM	0.1098 mL	0.5489 mL	1.0978 mL	2.7446 mL
	30 mM	0.0915 mL	0.4574 mL	0.9149 mL	2.2872 mL
	40 mM	0.0686 mL	0.3431 mL	0.6862 mL	1.7154 mL
	50 mM	0.0549 mL	0.2745 mL	0.5489 mL	1.3723 mL
	60 mM	0.0457 mL	0.2287 mL	0.4574 mL	1.1436 mL
	80 mM	0.0343 mL	0.1715 mL	0.3431 mL	0.8577 mL
	100 mM	0.0274 mL	0.1372 mL	0.2745 mL	0.6862 mL

(S)-10-Hydroxycamptothecin Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

(S)-10-Hydroxycamptothecin19685-09-710-HCPT 10-HydroxycamptothecinTopoisomeraseApoptosisCell-cyclearrestG2/MantitumorPCNAp53c-MycBcl-2Baxcaspase-1/3 rInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks